Metagenomi Management
Management criteria checks 2/4
Metagenomi's CEO is Brian Thomas, appointed in Sep 2016, has a tenure of 8.75 years. total yearly compensation is $6.06M, comprised of 10.4% salary and 89.6% bonuses, including company stock and options. directly owns 6.36% of the company’s shares, worth $4.21M. The average tenure of the management team and the board of directors is 2.4 years and 2.6 years respectively.
Key information
Brian Thomas
Chief executive officer
US$6.1m
Total compensation
| CEO salary percentage | 10.37% |
| CEO tenure | 8.8yrs |
| CEO ownership | 6.4% |
| Management average tenure | 2.4yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
Metagenomi, Inc.'s (NASDAQ:MGX) 26% Dip In Price Shows Sentiment Is Matching Revenues
Mar 16
Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential
Jan 28The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26%
Jan 28We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully
Jan 14Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry
Dec 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$78m |
| Dec 31 2024 | US$6m | US$628k | -US$78m |
| Sep 30 2024 | n/a | n/a | -US$74m |
| Jun 30 2024 | n/a | n/a | -US$75m |
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$8m | US$517k | -US$68m |
| Sep 30 2023 | n/a | n/a | -US$64m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$50m |
| Dec 31 2022 | US$2m | US$500k | -US$44m |
Compensation vs Market: Brian's total compensation ($USD6.06M) is above average for companies of similar size in the US market ($USD647.94K).
Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.
CEO
Brian Thomas (56 yo)
Dr. Brian Charles Thomas, Ph. D., is a Co-Founder of Metagenomi, Inc. (Fomerly, Metagenomi Technologies, LLC). He serves as Chairman of the Board of Metagenomi, Inc. since February 2024. He serves as Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.8yrs | US$6.06m | 6.36% $ 4.2m | |
| President | 4.4yrs | US$3.78m | 1.57% $ 1.0m | |
| Chief Financial Officer | 1.8yrs | US$3.58m | 0.044% $ 29.0k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Senior VP | 1.3yrs | no data | 0.0045% $ 3.0k | |
| Chief Medical Officer | 2.4yrs | US$2.04m | 0.11% $ 75.4k | |
| Head of Preclinical | 2.4yrs | no data | no data | |
| Head of Discovery | no data | no data | no data |
Experienced Management: MGX's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 1.3yrs | US$6.06m | 6.36% $ 4.2m | |
| President | no data | US$3.78m | 1.57% $ 1.0m | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Lead Independent Director | 3.8yrs | US$663.44k | 0.14% $ 90.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | no data | US$660.22k | 0.082% $ 54.1k | |
| Independent Director | 4.5yrs | US$657.99k | 2.06% $ 1.4m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: MGX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/04 21:55 |
| End of Day Share Price | 2025/06/04 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Metagenomi, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |